Canaccord Genuity Group Boosts GH Research (NASDAQ:GHRS) Price Target to $31.00

GH Research (NASDAQ:GHRS) had its price objective hoisted by Canaccord Genuity Group from $30.00 to $31.00 in a research report report published on Monday, Benzinga reports. They currently have a buy rating on the stock.

Several other research firms also recently issued reports on GHRS. HC Wainwright restated a buy rating and issued a $40.00 price target on shares of GH Research in a research note on Monday, March 4th. JMP Securities decreased their price target on shares of GH Research from $50.00 to $39.00 and set a market outperform rating on the stock in a research note on Friday, March 1st.

GH Research Price Performance

Shares of GHRS opened at $11.99 on Monday. The company’s 50-day moving average is $10.51 and its 200-day moving average is $8.07. The firm has a market capitalization of $623.84 million, a PE ratio of -19.98 and a beta of 0.80. GH Research has a fifty-two week low of $5.05 and a fifty-two week high of $14.64.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Analysts predict that GH Research will post -0.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GH Research

A number of hedge funds have recently added to or reduced their stakes in GHRS. AdvisorShares Investments LLC lifted its position in shares of GH Research by 4.3% during the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock valued at $280,000 after acquiring an additional 1,977 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in GH Research by 16.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 92,784 shares of the company’s stock worth $932,000 after purchasing an additional 12,911 shares during the period. PEAK6 Investments LLC grew its stake in GH Research by 72.9% during the third quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock worth $405,000 after buying an additional 16,991 shares in the last quarter. Barclays PLC increased its holdings in GH Research by 98.2% in the 3rd quarter. Barclays PLC now owns 63,590 shares of the company’s stock valued at $640,000 after buying an additional 31,500 shares during the period. Finally, Lynx1 Capital Management LP raised its position in shares of GH Research by 13.8% in the 3rd quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock valued at $11,087,000 after buying an additional 133,804 shares in the last quarter. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).